Abstract 3674
Background
CC is a public health problem in developing countries. Dissemination is typically lymphogenous but can develop hematogenous metastases. Chemotherapy alone is associated with a median SV of 13 months on metastatic disease. In selected cases with Isolated lung metastases (LM), PM is associated with prolonged SV.
Methods
Observational, retrospective cohort. Patients (ptes) with CC who underwent PM at the National Cancer Institute (INCan) Mexico from January 2005 to December 2017. Primary end-points were Overall Survival (OS) and Disease-Free Survival (DFS) Secondary end-points were morbidity and mortality of PM.
Results
A total of 29 ptes were identified. Squamous carcinoma was primary histology in 21 (72.4%). Most presented with advanced tumors at initial diagnosis, 11 (37.9%) stage II, 5 (17.2%) stage III and 7 (24.1%) stage IV. Unilateral nodules were seen in 27 (93.1%) and a single nodule was present in 24 (82.4%). Nodules were diagnosed as metachronous (after 6 months of diagnosis) in 21 (72.4%). Surgery was the initial treatment in 25 (86.2%) and only 4 (13.8%) received pre-operative chemotherapy. A wedge resection was performed in 16 (55.2%), interestingly, a lobectomy was needed in 12 cases (41.4%) and 1 case required a pneumonectomy. One case developed hemothorax requiring exploration for a 90-day morbity of 3.4% and 90-day mortality was 0%. An R0 resection was achieved in 26 (89.7%) On pathological analysis, only in 20 ptes (69%) LM were confirmed, in the other ptes a benign condition was diagnosed. Postoperative chemotherapy was indicated in 12 cases. Median follow up was 101.5 months (6 – 260). For SV analysis only ptes with proved LM were included. Median OS has not been reached, 5-year OS 35%. Median DFS 100 months (6.4 -193.5) Only R2 resection (p 0.05), no postoperative chemotherapy (p 0.025) and disease relapse (p 0.007) were statistically significantly associated with a worst SV.
Conclusions
In our cohort, PM is associated with better OS than chemotherapy alone. Although some ptes required a lobectomy, a very low morbidity and zero mortality in our cases is very encouraging. PM should be considered as fundamental part of multi-disciplinary treatment in cases of CC with isolated LM.
Clinical trial identification
Legal entity responsible for the study
Jose Francisco Corona-Cruz.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract